Abstract: Self-assembled coordination cages are interesting as drug delivery systems. Therefore, the synthesis of new M2L4 (M = Pd, Pt) molecular cages, derived from highly fluorescent, rigid polyaromatic ligands is reported and the first Pt2L4 cage with a ligand consisting of three pyridine moieties is described. Photophysical properties were examined showing high quantum yields  of up to 48% for the methoxy-functionalized ligands. Coordination of the ligands to palladium and platinum ions reduces the metallocages' fluorescence, however. The host-guest chemistry of the palladium cages with cisplatin is investigated confirming the encapsulation. The cages encapsulating cisplatin show a significantly increased cytotoxicity towards A549 (human lung adenocarcinoma) cells compared to cisplatin, and thus appear to be promising delivery vectors for the anticancer drug cisplatin.
Introduction
Almost two decades have passed, since McMorran and Steel reported the first Pd2L4 molecular cage, capable of enclosing a hexafluorophosphate counterion. [1] Since then increasing interest on M2L4 complexes with inner cavities has emerged, as they are readily accessible through self-assembly by simply mixing bidentate ligands and metal precursors. The assemblies rely largely on coordinative interactions of Pd 2+ and pyridine moieties, [2] although some examples with different metal ions, such as Pt 2+ , [3] Co 2+ , [4] Cu 2+ , [5] and Zn 2+ are known. [3a, 4e] So far only a few fluorescent M2L4 cages were obtained using ligands with extensive π-systems or attached fluorophores, [3a, 6] although highly fluorescent metallocages would be very interesting for biological imaging in cells by fluorescence microscopy. Aside from fluorescence, the encapsulation of (counter)ions has been reported. [4a-d, 5a, 7] Moreover, supramolecular coordination complexes are also capable to encapsulate metal compounds [2b, 6b, 8] (e.g. cisplatin) and some of them have been tested concerning their cytotoxicity for cancer cells. [8a-e, 9] Cisplatin is one of the most widely applied anticancer agent against ovarian, bladder and testicular cancer to name just a few. [10] However, its effectiveness is accompanied by severe side effects, thus limiting the applicable dose.
[10b] The necessity to reduce side effects and toxicity of cisplatin and its derivatives has gained growing appreciation in current research. One possibility is to utilize the so called EPR (= enhanced permeability and retention) effect, which was discovered in 1986 by Maeda and Matsamura. [11] Until now a plethora of vectors for cisplatin has been examined, e. g. liposomes, [12] nanoparticles, [13] macrocycles, [14] and as already mentioned above, also metallocages. [8c, g] Recently, our group evaluated palladium cage compounds as drug delivery systems for cisplatin in vitro in cancer cells and ex vivo in healthy rat liver tissue. [6e, 8a] Goal of this research is to ensure a safe transport of the active molecules selectively to the target entity. Solubility, toxicity and size of the transporter are of high importance in this context. Based on recent results, in this work the synthesis and characterization of new M2L4 molecular cages with enhanced solubility are described. The photophysical properties of the metallocages were investigated, in order to examine the possibility of uptake studies in cells. The incorporation of electron-donating methoxy groups in the ligand framework could potentially increase the photoluminescence of the ligands, thus enhancing the emissive properties of the metallocages. Moreover, the host guest relationship with cisplatin is examined for the palladium cages and the cytotoxicity of the cages and their cisplatin inclusion compounds towards human cancer cells is examined in vitro.
Results and discussion
Rigid bis-monodentate pyridyl ligands 2 and 3, bearing functionalizable methoxy moieties were obtained via divergent synthesis based on Sonogashira cross coupling reactions (Scheme 1). Compound 1 was synthesized in a two-step literature procedure. [15] A Sonogashira reaction of 1 with 3,5-dibromo aniline yielded 2 as a pale yellow solid after flash column chromatography. Likewise, reaction of 1 with 2,6-dibromo pyridine gave ligand 3 as a yellow solid after flash column chromatography. The methoxy-functionalization was supposed to have increased effects on the solubilty and fluorescence properties. Compounds 2 and 3 were characterized by 1 The cages were prepared from a suspension of stoichiometric amounts of the starting materials in acetonitrile by heating to reflux for one hour (Pd) or two days (Pt). For the platinum cage 3 Pt a purification step via column chromatography was necessary. Cage formation was validated by 1 H, DOSY NMR, ESI HRMS, and X-ray structure analysis. In 1 H NMR spectra, significant shifts are observed, when comparing the cages and the corresponding free ligands ( Figure 1 and Figure 2 ). As expected, upon coordination the whole signal sets are shifted downfield for each complex, especially the signals of Ha and Hb. These protons, located in ortho position to the coordinating pyridine nitrogen, receive the largest electron withdrawing influence of the metal cations (= 0.47 ppm -0.59 ppm). Diffusion-ordered NMR spectroscopy (DOSY) gives additional evidence for the formation of M2L4 cages. All proton signals of both ligands 2 and 3, and of the complexes 2
Pd
, 3
, and 3 Pt show the same diffusion coefficient (D). The ratio Dligand to Dcomplex is approximately 2:1, which is due to the presence of larger cage molecules in solution. Using the Einstein-Stokes correlation, [16] the Stokes radii r0 were calculated for each cage compound. The values are given in Table 1 . Pd crystallizes in the triclinic space group P with the inversion center located centrally inside the cavity ( Figure 5 ).
Each Pd
II ion is coordinated in a square-planar fashion by pyridyl moieties of four molecules 2 (angles N-Pd-N between 88.6(1)° and 90.8(2)°), resulting in a lantern-shaped cage with a central cavity. The latter is stocked with disordered solvent molecules, not with counterions. The anions are disordered and located outside the cage, half of them at the apical position of Pd. These observations are in accordance to previously reported results, [8g] although numerous examples of M2L4 cage compounds with encapsulated counterions exist in literature as well. [1, 6a, 7a, 17] The cage diameter, calculated between two opposing methoxymoieties is ≈ 22.6 Å (averaged distances between outer hydrogen atoms). This fits the value calculated from diffusion coefficients (≈ 22.9 Å) well ( Table 1 ). The Pd … Pd distance is 12.0 Å, diagonally opposing central carbon atoms display an averaged distance of 10.5 Å. Cage 3 Pd also crystallizes in the triclinic space group P with an inversion center located centrally inside the cage ( Figure 6 ). The Pd II ions are again coordinated in a square-planar fashion to one pyridyl moiety of four ligand molecules 3. The resulting lanternshaped cage compound exhibits a central cavity that is occupied by two non-disordered acetone molecules. The respective carbonyl oxygen atoms are pointing to the metal ions with a distance of Pd . The cage diameter calculated between two opposing methoxy-moieties is ≈ 22.4 Å (averaged distances between outer hydrogen atoms), which correlates well with the value calculated from diffusion coefficients (≈ 21.9 Å, Table 1 ). The distance between the two Pd atoms is 11.6 Å, diagonally opposing central pyridine N display an averaged distance of 10.9 Å. . Thermal ellipsoids are shown at a 50% probability level. Side view, drawn with two encapsulated acetone molecules (spacefilling representation at 100% of van-der-Waals radii, visualizing the steric demand inside the cage; H and counter ions omitted for clarity. Element colors: C -grey, N -blue, O -red, Pd -turquoise). is slightly sensitive to oxygen and thus has to be stored under an argon atmosphere.
The ligands' and cages' photophysical properties show a striking dependence on the coordination of metal ions, especially concerning photoluminescence. The absorption spectra of ligand 2 and its corresponding cage are depicted in Figure 7 . Ligand 2 displays its strongest absorption bands between 210 and 320 nm and a weaker band is located between 330 and 370 nm. The absorption maximum is observed at 223 nm, with an extinction coefficient 223 (2) = 47700 l·mol
II a bathochromic shift of 9 nm is observed and absorption increases by 3.78 (232 (2 Pd ) = 180500 l·mol While absorption properties of 2 and 3 show a minor influence of metal coordination, luminescence is strongly dependent of the metal. Excitation of a solution of 2 in acetonitrile with UV light leads to a strong emission (290 nm (2) = 42%), with a maximum at λem,max (2) = 412 nm. However, coordination to Pd II lowers significantly the quantum yield (310 nm (2 Pd ) = 7%), while the emission maximum remains almost unaffected λem,max (2 Pd ) = 413 nm, Δλem,max = 1 nm), as depicted in Figure 9 .
This article is protected by copyright. All rights reserved Ligand 3 shows an even higher quantum yield (300 nm (3) = 48%), and as intended, the methoxy-functionalization leads to a significantly increased fluorescence compared to the unsubstituted ligand (48% vs. 1.1% ). [6a] Analogous to 2, upon coordination of Pd II , the quantum yield is lowered significantly to  300 nm (3 Pd ) = 3%, the emission maximum is bathochromically shifted from λem,max (3) = 345 nm to em,max (3 Pd ) = 352 nm. Platinum cage 3
Pt is hardly emissive with a quantum yield of less than 0.2%. The emission maximum is almost the same as for 3 Pd (em,max (3 Pd ) = 349 nm). The emission spectra of all three compounds are shown in Figure 10 . Unfortunately, uptake studies of the cages in cells by fluorescence microscopy could not be performed due to low photoluminescence. To examine the encapsulation properties of the palladium cages, solutions of 2 Pd and 3 Pd were treated with distinct amounts of cisplatin and analyzed by NMR spectroscopy. Convincing evidence for cisplatin encapsulation, both in 2 Pd and 3 Pd was received. Successive addition of 2 and 10 equivalents of cisplatin in DMF-d7 to a DMF-d7 solution of 2 Pd results in a significant broadening of the He signals. These hydrogen atoms are pointing directly into the cages inner cavity and thus apparently interact with encapsulated cisplatin guest molecules ( Figure 11) . The other signals remain unaffected. This behavior is consistent with a similar example reported earlier and was described as an indication for the encapsulation of cisplatin.
[8a] 
2
Pd with 2 equiv. cisplatin, c) 2 Pd with 10 equiv. cisplatin.
Addition of 2 equivalents of cisplatin to a CD3CN solution of cage 3 Pd , heating to 60 °C for 10 min and finally ultrasonic treatment for 2 min leads to a distinct, macroscopically visible dissolution of cisplatin. The 1 H NMR spectrum gives also evidence for the encapsulation. Primarily the signal from Ha is broadened noticeably and furthermore shifted downfield, thus indicating an interaction with encapsulated guest molecules ( Figure 12 ). This is consistent with similar literature results. [8a, f, g] Alike experiments with 3 Pt resulted in decomposition products. The palladium cages 2 Pd and 3 Pd as well as their respective ligands 2 and 3 and the palladium precursor [Pd(NCCH3)4](BF4)2 were screened for their antiproliferative properties in vitro in human cancer cell lines A549 (lung carcinoma) and HepG2 (hepatocellular carcinoma). [18] The IC50 (inhibitory concentration to reduce viability to 50%) values of the compounds were determined after 48 hours incubation using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-zolium bromide (MTT) assay (Table 2 ). The cage compound 3 Pd showed moderate cytotoxicity (IC50 = 44-72 µM) in the tested cell lines and is less effective compared to cisplatin, while cage 2 Pd is non-cytotoxic. In contrast, the ligands and the Pd precursor are inactive (IC50 > 100 µM) in A549 and HepG2. As previously reported, [8a, g] this type of metallocages can potentially function as drug delivery systems due to their ability to encapsulate two molecules cisplatin.
1 H NMR studies provide evidence of the encapsulation of cisplatin within cage 2 Pd and 3 Pd (see Figure 11 and Figure 12 ). The antiproliferative effects of the host-guest complexes [(cisplatin)2  2 Pd ] and [(cisplatin)2  3 Pd ] were studied against human carcinoma A549 and HepG2 ( Figure 13) . Notably, both host-guest systems show an increased cytotoxic effect in A549 compared to cisplatin and the cage by itself, while in HepG2 these systems are similar effective or even less potent than cisplatin. The low cytotoxicity of the cage compounds and the enhanced cytotoxic effect of the host-guest systems compared to cisplatin make these metallocages attractive candidates as drug delivery systems. 
Conclusion
The synthesis and characterization of new M2L4 (M = Pd, Pt) molecular cages 2
Pd
, 3 Pd and 3
Pt
, starting from rigid, highly fluorescent, ligands 2 and 3 is described. The first Pt2L4 cage with a rigid tris-pyridine ligand (3) is presented. Additionally, absorption and photoluminescence studies of both ligands and cages have been performed, showing a lower fluorescence of the metallocages in comparison to the highly fluorescent free ligands. It could be demonstrated that both 2 Pd and 3 Pd are capable of encapsulating the anticancer drug cisplatin. Notably, the palladium precursor and the ligands are non-toxic and the palladium cages possess only a low cytotoxicity in cancer cells. However, the cage compounds encapsulating cisplatin show an increased cytotoxic effect towards human lung cancer cells (A549). Thus, the methoxy-functionalized coordination cages are promising drug delivery vectors for the anticancer agent cisplatin. Further ligand modifications are currently performed in our laboratories to increase cage fluorescence.
Experimental section

General remarks
All chemicals were purchased from commercial sources and used without further purification, solvents were distilled prior to use. NMRspectra were recorded on a Bruker AV 400 or a Bruker AV 400 HD spectrometer. IR spectra were collected on a Varian 670 spectrometer. ESI HRMS measurements were conducted on a Thermo LTQ FT Ultra. UV/Vis spectra were recorded on an Agilent Cary 60. Emission spectra and absolute quantum yields were obtained on a Hamamatsu Absolute PL QY spectrometer C11347. Compound 1 was synthesized according to literature procedures. [15] 3,5-Bis-( (5-methoxypyridin-3-yl)-ethynyl)-aniline (2) Compound 1 (1.00 g, 7.76 mmol, 4.00 equiv.), 3,5-dibromoaniline (471 mg, 1.88 mmol, 1.00 equiv.), CuI (35.8 mg, 0.19 mmol, 0.10 equiv.) and [PdCl2(PPh3)2] (132 mg, 0.19 mmol, 0.10 equiv.) are suspended in degassed NEt3 (40 ml) and heated to reflux for three days under an argon atmosphere. The suspension is filtered over celite, the filter cake washed with CH2Cl2 and the solvent removed under reduced pressure. The crude product is purified by flash chromatography (CH2Cl2 : MeOH = 100 : 0 → 96 : 4). The product 2 is obtained as yellow needles (281 mg, 791 µmol, 42%). 2, 149.6, 145.0, 138.7, 124.4, 124.1, 122.9, 121.0, 100.9, 92.3, 86.4, 56.5 4, 149.8, 145.6, 139.0, 128.0, 124.6, 124.0, 123.5, 119.2, 95.3, 84.0, 57.7 
2,6-Bis-((5-methoxypyridin-3-yl)-ethynyl)-pyridine (3)
3-Ethynyl-5-methoxy pyridine (787 mg, 5.91 mmol, 4.00 eq), 2,6-dibromopyridine (350 mg, 1.48 mmol, 1.00 eq), CuI (28.1 mg, 148 µmol, 0.10 eq) and [PdCl2(PPh3)2] (104 mg, 148 µmol, 0.10 eq) are suspended in degassed NEt3 (27 ml) and heated to reflux for three days under an argon atmosphere. The suspension is filtered over celite, the filter cake washed with CH2Cl2 and the solvent removed under reduced pressure. The crude product is purified by flash chromatography (CH2Cl2 : MeOH = 99 : 1 → 96 : 4) and product 3 obtained as an off-white solid (420 mg, 1.23 mmol, 83%).
1
This article is protected by copyright. All rights reserved Accepted Manuscript FULL PAPER 143.4, 138.6, 136.9, 126.9, 122.7, 119.5, 90.9, 86.4, 55.8 5, 146.0, 143.3, 139.8, 138.7, 129.4, 128.7, 123.7, 94.1, 83.3, 57.8 A mixture of 3 (25.4 mg, 74.3 µmol, 4.00 eq), [PtCl2(NCCH3)2] (12.9 mg, 37.1 µmol, 2.00 eq) and AgClO4 (15.4 mg, 74.3 µmol, 4 .00 eq) is dispersed in 3 ml acetonitrile and heated to reflux for 2 days in the dark. The dispersion is filtered, the product precipitated by addition of diethyl ether (30 ml) and centrifuged. The crude product is dissolved in acetonitrile, filtered over silica and the silica washed with acetonitrile (20 ml). The product is eluted from silica with a mixture of acetone : methanol : water : KNO3(aq) (sat.) = 24 : 12 : 3 : 1. The organic solvents are evaporated under reduced pressure, the solid centrifuged off, dissolved in acetonitrile and filtered. After addition of 1 mL sat. aqueous LiClO4 the organic solvents are evaporated under reduced pressure, the product centrifuged off the resulting dispersion, washed with water (2 × 10 ml), ethanol (2 ml) and diethyl ether (10 mL) and dried in vacuo. 3 Pt is obtained as a pale brown solid (8.00 mg, 3.72 µmol, 20%). 8, 147.0, 143.3, 140.9, 138.7, 129.4, 129.1, 123.9, 94.0, 83.1, 58.0 
MTT cytotoxicity assay standard procedure:
This essay was performed in 96 well plates. A549/HepG2 cells were grown to 30-40 % confluence. The medium was removed and 100 µL medium /well containing 1 µL DMF compound stock were added to the cells and incubated for 48 h. All concentrations as well as a DMF control were tested in technical triplicates and biological duplicates. 20 µL Thiazolyl Blue Tetrazolium bromide (5 mg/mL in PBS, Sigma Aldrich) were added to the cells and incubated for 2-4 h until complete consumption was observed. After removal of the medium, the resulting formazan was dissolved in 200 µL DMSO. Optical density was measured at 570 nm (562 nm) and background subtracted at 630 nm (620 nm) by a TECAN Infinite® M200 Pro. For calculation of IC50 values, residual viabilities for the respective compound concentration were fitted to viability [%] , inhibitor concentration [µM] and Hill slope using Graphpad Prism 6.0.
Crystallographic details
Additional details of the crystallographic measurements can be found in the Supporting Information. CCDC numbers: 1453095-1453096.
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